A fresh approach to beat genital herpes

Based on ground-breaking research from the University of Gothenburg Simplexia has developed a novel and unique vaccine approach for the genital herpes virus.

A vaccine for genital herpes using a radically different scientific approach

The Simplexia vaccine approach is based upon the observation that HSV-1 infection, oral herpes, acquired during childhood does not provide protection against later HSV-2 (genital herpes) infection. Consequently our HSV-2 vaccine candidate contains a protein, glycoprotein G-2, that is unique for HSV-2.

“By focusing on the G-2 (gG-2) protein our approach has used the experiences from earlier research. Yet, it is a completely new approach for treating and preventing genital herpes.”

Tim Wood

CEO Simplexia AB

The unmet clinical need

A Silent Epidemic

Many people with genital herpes aren't even aware that they're infected with the virus and may not find out they are infected until they pass it on to a subsequent partner who develops symptoms.

Targeting a global pandemic

HSV-1 and HSV-2 cause lifelong, incurable infections. According to the WHO, More than 3.7 billion people under the age of 50 around the world are infected with HSV-1, while over 400 million people between have HSV-2.

Providing a long-term solution

Since current therapies with anti-herpes virus medications only attack activated virus, they are less than 50% effective in reducing transmission between partners. Simplexia's approach provides a long-term solution.

For those who do not know they need it

After infection the virus moves to nerve cells where they lie dormant. It may occasionally be activated to cause symptoms, however many people do not realise that they are infected.

Also including severe, lesser known indications

As well as genital sores and blister, HSV-2 can occasionally cause brain infection and a wide range of severe neonatal disease.

Some words from our team